Development Stage: IND stage
Key Asset Highlights:
（1）Features a innovative trispecific antibody design co-targeting CD19, BCMA and CD3, achieving dual B-cell lineage depletion and precise T-cell redirection for synergistic autoimmune disease intervention.
（2）Simultaneously eliminates CD19-positive mature B cells and BCMA-positive plasma cells, effectively reducing pathogenic autoantibody production and suppressing persistent autoimmune inflammatory responses in SLE and LN.
（3）The dual-antigen targeting strategy significantly improves the coverage of autoreactive B-cell populations compared with single or dual-targeted therapeutics, delivering more comprehensive and durable disease control.
（4）Precisely modulates aberrant adaptive immune responses while retaining normal immune homeostasis, exhibiting a differentiated safety profile and lower relapse risk for refractory autoimmune diseases.
（5）Demonstrates excellent biochemical stability and favorable developability in preclinical studies, supporting smooth IND submission and subsequent clinical exploration for lupus-spectrum disorders.
（6）Backed by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for SLE and lupus nephritis treatment.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
